Can J Gastroenterol Hepatol. 2014 Mar;28(3):150-4. doi: 10.1155/2014/561732.
To determine whether there is a significant difference in tumour stage between patients initially found with hepatocellular carcinoma (HCC) at a tertiary hepatobiliary centre and patients referred with tumours detected elsewhere; and to determine variables associated with referral in a palliative stage.
A retrospective review of 12,199 patients seen at a liver clinic over a 10.5-year period revealed 236 patients with HCC first detected internally (internal) and 163 who were referred with a known mass (referred). All patients were staged at the time of treatment using the Milan criteria for transplantation and Barcelona Clinic Liver Cancer (BCLC) staging system. Curative disease was defined as BCLC stages 0 and A. In the referred group, univariate and multivariate analyses were used to determine which of the following factors were significantly associated with presentation in a palliative stage: age, sex, ethnicity, cause of liver disease, presence of cirrhosis, location of residence and quintile of neighbourhood income.
In comparing the internal versus referred patients, significant differences were found in the proportion of patients fulfilling Milan criteria (72% versus 36%), those with curative disease (75% versus 49%) and those with very early stage tumour (BCLC stage 0, 23% versus 7%); all differences were statistically significant (P<0.001). In patients referred for treatment of HCC from an outside institution, none of the variables tested were associated with presentation in a palliative stage.
Patients with HCC referred to a liver treatment centre were more likely to be in palliative stages than those whose tumour was detected internally.
确定在三级肝胆中心最初发现肝细胞癌 (HCC) 的患者与因其他地方发现肿瘤而转诊的患者之间肿瘤分期是否存在显著差异;并确定在姑息治疗阶段与转诊相关的变量。
对在肝科诊所就诊的 12199 例患者进行回顾性分析,发现 236 例 HCC 患者最初在内部发现(内部),163 例患者因已知肿块转诊(转诊)。所有患者在治疗时均根据米兰标准用于移植和巴塞罗那临床肝癌 (BCLC) 分期系统进行分期。治愈性疾病定义为 BCLC 分期 0 期和 A 期。在转诊组中,使用单变量和多变量分析来确定以下哪些因素与姑息治疗阶段的表现显著相关:年龄、性别、种族、肝病病因、肝硬化存在、居住地位置和社区收入五分位数。
在比较内部与转诊患者时,在符合米兰标准的患者比例(72% 对 36%)、具有治愈性疾病的患者比例(75% 对 49%)和非常早期肿瘤患者比例(BCLC 分期 0 期,23% 对 7%)方面存在显著差异;所有差异均具有统计学意义(P<0.001)。在因 HCC 从外部机构转诊接受治疗的患者中,测试的变量均与姑息治疗阶段的表现无关。
与在内部发现肿瘤的患者相比,转诊到肝脏治疗中心的 HCC 患者更有可能处于姑息治疗阶段。